Ryvu Therapeutics

Biotechnology ResearchLesser Poland, Poland201-500 Employees

Ryvu Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel small molecule therapies for cancer. Its internally discovered pipeline explores diverse mechanisms informed by cancer biology, including kinase inhibition, synthetic lethality, and immuno-oncology approaches. Its lead programs include RVU120, a selective CDK8/CDK19 inhibitor in early clinical development for hematologic malignancies and solid tumors, and SEL24 (MEN1703), a dual PIM/FLT3 inhibitor licensed to Menarini currently in Phase II for AML. Ryvu has established partnerships with global companies including Merck, Menarini, Galapagos, Exelixis, and BioNTech. Founded in 2007 and headquartered in Kraków, Lesser Poland, the company is listed on the Warsaw Stock Exchange as part of the sWIG80 index; in 2025 it formed a strategic collaboration with BioNTech US Inc. to support trial site activation and patient recruitment for BioNTech's oncology therapies in Poland.

Sign up for free to view info

Email Format Employee directory